Board of Directors

Welcome to the Consort Medical team.

Dr Peter Fellner (70)

Chairman

Appointed to the Board
14 November 2005. Chairman since May 2009.

Current Roles
Dr Fellner is currently Chairman of Vernalis plc, Optos plc, and Ablynx nv. He is also a member of the Novo A/S Advisory Group.

Committee Membership
Dr Fellner is Chairman of the Nomination Committee.

Past Roles & Experience
Dr Fellner previously served as Chairman of Celltech Group plc from 2003 to July 2004, having been CEO from 1990 onwards. Before joining Celltech he was CEO of Roche UK from 1986 to 1990. More recently he served as Chairman of Biotie Therapies Corp. from 2010 to 2014, and as Chairman of Acambis plc from 2006, until its acquisition by Sanofi Aventis in 2008, and as Chairman of Premier Research Group plc from 2007 to 2008, when it was acquired by a private-equity backed group. In addition, he was Vice Chairman of Astex Pharmaceuticals, Inc from 2011 to 2013 and a director of the global biopharmaceutical company UCB SA from 2005 to April 2014. He also served as a director of QinetiQ Group plc and Evotec AG.
Dr Fellner has many years' experience in the pharmaceutical and biotechnology industry in a variety of roles including research and development and senior executive and non-executive positions.

Jonathan Glenn (45)

Chief Executive Officer

Appointed to the Board
11 September 2006. CEO since December 2007.

Current Roles
Chief Executive Officer

Committee Membership
Mr Glenn is a member of the Nomination Committee and the Corporate Responsibility Committee.

Past Roles & Experience
Jonathan was Group Finance Director of Consort Medical plc from September 2006 to December 2007 until he took up the position of Chief Executive Officer in December 2007. Prior to joining Consort Medical plc, Jonathan was global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge-based developer of instrumentation for the Life Sciences industry.
Mr Glenn is a Chartered Accountant.

Richard Cotton (53)

Group Finance Director & Company Secretary

Appointed to the Board
25 June 2012

Current Roles
Group Finance Director.

Past Roles & Experience
From 2008 to 2011 Richard was Group Finance Director of Vitec Group plc. From 2005 to 2008 he was Group Finance Director at Wagon plc and from 2001 to 2005 Group Finance Director of McLeod Russell plc.
Mr Cotton is a Chartered Management Accountant.

Steve Crummett (49)

Non-Executive Director

Appointed to the Board
13 June 2012

Current Roles
Finance Director of Morgan Sindall Group plc

Committee Membership
Mr Crummett is Chair of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee.

Past Roles & Experience
Previously Steve was Group Finance Director of Filtrona plc (now Essentra plc) from 2008 to 2012. From 2003 to 2006 Steve was Group Director, Mergers & Acquisitions at Excel plc and previously held senior finance roles with McKechnie plc and Logica plc.
Mr Crummett is a Chartered Accountant.

Ian Nicholson (53)

Non-Executive Director

Appointed to the Board
13 June 2012

Current Roles
Ian is also Chief Executive Officer of F2G Ltd, a UK-based anti-fungal drug discovery and development company, Chairman of Bioventix Ltd, a diagnostics company, non-executive director of Clinigen Group plc, a specialty pharmaceuticals and services business, and also an Operating Partner at Advent Life Sciences LLP.

Committee Membership
Mr Nicholson is Chair of the Corporate Responsibility Committee and a member of the Nomination Committee.

Past Roles & Experience
From 2004 to 2012 Ian was Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company and from 2000 to 2004 Senior Vice President, Business Development at Celltech Group plc, then the UK's largest biotechnology company.
In addition to his CEO experience Mr Nicholson has extensive experience in business development, licensing and mergers and acquisitions in the UK, Europe and the US.

Dr William Jenkins (66)

Non-Executive Director

Appointed to the Board
6 May 2009. Senior Independent Director since 1 September 2011

Current Roles
William is a non-executive director of Ablynx nv, Allecra Therapeutics GmbH and AlloCyte Pharmaceuticals AG. He is also an ad hoc member of the board of Evotec AG and a member of their Scientific Advisory Board as well as a member of the Scientific Advisory Board of BB Biotech Ventures and a member of the Strategic Advisory Board of Chiesi Farmaceutici SpA. He is principal of William Jenkins Pharma Consulting.

Committee Membership
Dr Jenkins is Chair of the Remuneration Committee and a member of the Nomination Committee.

Past Roles & Experience
Formerly head of Worldwide Clinical Development and Regulatory Affairs for Novartis Pharma AG and held similar positions with Ciba Geigy AG and Glaxo.
Dr Jenkins has been advising a wide range of pharma and biotech companies and investment and venture capital firms in the healthcare sector since 1999.

Dr Lynn Drummond (54)

Non-Executive Director

Appointed to the Board
9 February 2011

Current Roles
Dr Drummond is the non-executive Chairman of InFirst Healthcare Limited and Venture Life Group plc, both of which are consumer healthcare companies. She is also a non-executive director of Allocate Software plc, the leading workforce optimisation and compliance software applications provider and Shield Holdings AG, a speciality mineral medicines pharmaceutical company.

Committee Membership
Dr Drummond is a member of the Audit Committee and a member of the Nomination Committee.

Past Roles & Experience
Dr Drummond was previously Managing Director at Rothschild where her focus was on advising clients within the healthcare sector. Prior to this she worked in the Cabinet Office as Private Secretary to the Chief Scientific Advisor. She is a Fellow of the Royal Society of Edinburgh and the Royal Society of Chemistry.